The Federal Trade Commission on Friday said convicted fraudster Martin Shkreli should be held in contempt of court for launching a new drug company after he was banned from the pharmaceutical industry for life.
An earlier court order prohibited Shkreli “from directly or indirectly participating in any manner in the pharmaceutical industry” and ordered him to pay up to $65 million in monetary relief. Shkreli in 2018 was sentenced tofor securities fraud. He served four years from Pennsylvania’s Allenwood Low Federal Correctional Institution in May of 2022.
The FTC asked the United District Court for the Southern District of New York to find Shkreli in civil contempt for failing to satisfy the monetary judgment and for forming a new company, called Druglike, described as “a platform for democratizing the access, costs and rewards of early-stage drug discovery.”
The agency also said Shkreli has not complied with requests to turn over information and make himself available for interviews related to its probe into Druglike.
An attorney for Shkreli did not immediately reply to a request for comment.
Shkreli, once dubbed the “Pharma Bro,” described Druglike in a July 25, 2022, press release as a “Web3 drug discovery software platform.” The technology will speed the development of new drugs and benefit “underserved” communities with rare diseases or in developing markets, he said.
Shkreli drew a barrage of criticism in 2015 when he hiked the cost ofduring his tenure as chief executive of Turing Pharmaceuticals. But his legal woes stemmed from a 2018 conviction for in two hedge funds.
Thanks for reading CBS NEWS.
Create your free account or log in
for more features.